What is IntegraSkin
Is a personalised medicine company that combining OMIC technologies
and Artificial Intelligence identify the optimal treatment for
patients with Chronic inflammatory skin conditions (CISCs).
It is estimated that up to 87% of the human population may suffer from some skin disorder during their lives (McKoy et al. 2015, The importance of dermatology in global health). The most affected fraction of this population are individuals with Chronic Inflammatory Skin Conditions (CISCs), such as atopic eczema, psoriasis, chronic urticaria, nummular eczema, contact dermatitis. Severe CISCs cases have wounds, rashes, and itchy lesions all over the body, abolishing any social integration and seriously impairing lives‘ personal and professional success.
Most cases suffering from severe CISCs lack medication to keep their symptoms under control and spend their lives doing trial-and-error with different drugs, which can result in serious side effects.
IntegraSkin (ISK) is committed to providing the most accurate therapy for each CISC patient by leveraging the power of AI and OMICs technologies for precision medicine. In doing so, ISK also identifies therapeutic targets involved in the disease mechanisms of patients‘ subpopulations to facilitate the development of targeted therapies.
The emergence of novel OMIC technology, for example, new generation sequencing, proteomics, and single-cell transcriptomics enable us to identify up to:
- 18 000 different mRNAs in histological skin sections [whole transcriptome]
- 10 000 different skin inflammation-relevant proteins
- 200 markers for multiparametric immunophenotyping of:
- Blood leukocytes
- Cutaneous resident and infiltrating cells
- 23 blood soluble factors
- 2400 inflammatory cellular mechanisms
These technologies, combined with our expertise in study design, tissue processing protocols, databases, and proprietary AI algorithms, allow identifying disease mechanisms in each patient suffering from CISCs.
Understand how
IntegraSkin works.
¿What kind of customer are you?
Choose to which one you belong
